[1] |
RAJMAN L, CHWALEK K, SINCLAIR D A. Therapeutic potential of NAD-boosting molecules: the in vivo evidence[J]. Cell Metab,2018,27(3):529-547. doi: 10.1016/j.cmet.2018.02.011 |
[2] |
OKABE K, YAKU K, TOBE K, et al. Implications of altered NAD metabolism in metabolic disorders[J]. J Biomed Sci,2019,26(1):34. doi: 10.1186/s12929-019-0527-8 |
[3] |
PODDAR S K, SIFAT A E, HAQUE S, et al. Nicotinamide mononucleotide: exploration of diverse therapeutic applications of a potential molecule[J]. Biomolecules,2019,9(1):E34. doi: 10.3390/biom9010034 |
[4] |
REVOLLO J R, KÖRNER A, MILLS K F, et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme[J]. Cell Metab,2007,6(5):363-375. doi: 10.1016/j.cmet.2007.09.003 |
[5] |
JUKARAINEN S, HEINONEN S, RÄMÖ J T, et al. Obesity is associated with low NAD(+)/SIRT pathway expression in adipose tissue of BMI-discordant monozygotic twins[J]. J Clin Endocrinol Metab,2016,101(1):275-283. doi: 10.1210/jc.2015-3095 |
[6] |
LEE C F, CHAVEZ J D, GARCIA-MENENDEZ L, et al. Normalization of NAD+ redox balance as a therapy for heart failure[J]. Circulation,2016,134(12):883-894. doi: 10.1161/CIRCULATIONAHA.116.022495 |
[7] |
ZHAO Y, GUAN Y F, ZHOU X M, et al. Regenerative neurogenesis after ischemic stroke promoted by nicotinamide phosphoribosyltransferase-nicotinamide adenine dinucleotide cascade[J]. Stroke,2015,46(7):1966-1974. doi: 10.1161/STROKEAHA.115.009216 |
[8] |
LI C, ZHOU Y N, RYCHAHOU P, et al. SIRT2 contributes to the regulation of intestinal cell proliferation and differentiation[J]. Cell Mol Gastroenterol Hepatol,2020,10(1):43-57. doi: 10.1016/j.jcmgh.2020.01.004 |
[9] |
GHOSH S, DAPERNO M. Topical therapy in ulcerative colitis: always a bridesmaid but never a bride?[J]. Gastroenterology, 2015, 148(4): 701-704. |
[10] |
ORDÁS I, ECKMANN L, TALAMINI M, et al. Ulcerative colitis[J]. Lancet,2012,380(9853):1606-1619. doi: 10.1016/S0140-6736(12)60150-0 |
[11] |
YAN Y X, SHAO M J, QI Q, et al. Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages[J]. Acta Pharmacol Sin,2018,39(10):1633-1644. doi: 10.1038/aps.2017.185 |
[12] |
FORD A C, MOAYYEDI P, HANAUER S B. Ulcerative colitis[J]. BMJ,2013,346:f432. doi: 10.1136/bmj.f432 |
[13] |
MOWAT C, COLE A, WINDSOR A, et al. Guidelines for the management of inflammatory bowel disease in adults[J]. Gut,2011,60(5):571-607. doi: 10.1136/gut.2010.224154 |
[14] |
JIA S H, LI Y, PARODO J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical Sepsis[J]. J Clin Invest,2004,113(9):1318-1327. doi: 10.1172/JCI19930 |
[15] |
MEIER F M, FROMMER K W, PETERS M A, et al. Visfatin/pre-B-cell colony-enhancing factor (PBEF), a proinflammatory and cell motility-changing factor in rheumatoid arthritis[J]. J Biol Chem,2012,287(34):28378-28385. doi: 10.1074/jbc.M111.312884 |
[16] |
MOSCHEN A R, KASER A, ENRICH B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties[J]. J Immunol,2007,178(3):1748-1758. doi: 10.4049/jimmunol.178.3.1748 |
[17] |
STARR A E, DEEKE S A, NING Z B, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC[J]. Gut,2017,66(9):1573-1583. doi: 10.1136/gutjnl-2015-310705 |
[18] |
XU T Y, ZHANG S L, DONG G Q, et al. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase[J]. Sci Rep,2015,5:10043. doi: 10.1038/srep10043 |
[19] |
ZHANG S L, LI Z Y, WANG D S, et al. Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells[J]. Acta Pharmacol Sin,2020,41(6):763-770. doi: 10.1038/s41401-019-0343-4 |
[20] |
VERDIN E. NAD+ in aging, metabolism, and neurodegeneration[J]. Science,2015,350(6265):1208-1213. doi: 10.1126/science.aac4854 |
[21] |
PREISS J, HANDLER P. Biosynthesis of diphosphopyridine nucleotide. I. Identification of intermediates[J]. J Biol Chem,1958,233(2):488-492. |
[22] |
DE FIGUEIREDO L F, GOSSMANN T I, ZIEGLER M, et al. Pathway analysis of NAD+ metabolism[J]. Biochem J,2011,439(2):341-348. doi: 10.1042/BJ20110320 |
[23] |
FREDERICK D W, LORO E, LIU L, et al. Loss of NAD homeostasis leads to progressive and reversible degeneration of skeletal muscle[J]. Cell Metab,2016,24(2):269-282. doi: 10.1016/j.cmet.2016.07.005 |
[24] |
MOSCHEN A R, GERNER R, SCHROLL A, et al. A key role for Pre-B cell colony-enhancing factor in experimental hepatitis[J]. Hepatology,2011,54(2):675-686. doi: 10.1002/hep.24416 |
[25] |
HASMANN M, SCHEMAINDA I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis[J]. Cancer Res,2003,63(21):7436-7442. |